Virtual
Event Title
Efficacy of Monoclonal Antibodies in the Context of Rapidly Evolving SARS-CoV-2 Variants
December 15, 2022
- Date:
- December 15, 2022
Time: 13:00-17:00 Central European Time | 7:00 AM-11:00 AM United States EST
OBJECTIVES
This meeting will be held in virtual format only. FDA and EMA seek to bring together scientists, clinicians, industry representatives and regulators to discuss alternative strategies to support the development of novel monoclonal antibody therapies including those based on prototype products that have demonstrated safety and efficacy in clinical trials.
Note: This meeting is intended for experts in the field and/or people actively involved in the topic of the meeting.
REGISTRATION:
This meeting will be held in virtual format only. Advanced registration is required for online observer attendance. To register for this workshop and receive the meeting link, please use the link here.
Registration link: https://ema-europa.webex.com/weblink/register/rb669ba46a94393b5b66ec5683556db72
MEETING MATERIALS
A full agenda is attached here. Please note that other meeting materials will not be available.
Event Materials
Title | File Type/Size |
---|---|
Agenda Joint EMA-FDA Workshop Efficacy of monoclonal antibodies in the context of rapidly evolving SARS-CoV-2 variants | pdf (275.90 KB) |